Back to Tirzepatide research
tirzepatide gip agonist review 2026-04-23 EuropePMC

Natural Products Explored for Obesity Treatment Mechanisms in Review

Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions

Background

The global obesity epidemic represents one of the most pressing public health challenges, characterized by excessive adipose tissue accumulation that significantly impairs health and quality of life. According to the World Health Organization (WHO), global obesity prevalence has tripled since 1975, with over 2.5 billion adults classified as overweight or obese in 2022. This alarming trajectory underscores the urgent need for effective and safe therapeutic strategies, especially exploring the potential of natural products to address obesity mechanisms and offer new treatment avenues.

Results

While this review article itself does not present novel experimental findings, it highlights the severe and escalating global burden of obesity as the primary context for its investigation into natural products. The World Obesity Atlas 2025 projects that by 2035, over 1.13 billion adults will be living with obesity, representing a staggering 115% increase from 2010 levels. This trajectory indicates that the number of adults with obesity is expected to more than double in just 25 years. The review emphasizes that this increase is observed globally, particularly rapidly in low- and middle-income countries, stressing the urgent need for accessible and effective interventions to curb this public health crisis.

Why It Matters

This review is crucial because it highlights the escalating global obesity crisis and the urgent need for novel, potentially safer, and more accessible therapeutic options. By systematically exploring natural products, it could pave the way for the development of new anti-obesity drugs or complementary therapies, potentially reducing the reliance on synthetic compounds with known side effects. Future research should focus on rigorous preclinical validation and subsequent Phase II and Phase III human trials for promising natural compounds identified in such comprehensive reviews.


tirzepatide gip agonist glp 1 agonist
Source: europepmc:epmc_PMC13093847 · Ingested 2026-04-23 · Digest: gemini-2.5-flash